Drug Profile
Research programme: heteroaryl oxazolidinones - Bayer
Alternative Names: Heteroaryl oxazolidinones research programme - BayerLatest Information Update: 09 Jul 2002
Price :
$50
*
At a glance
- Originator Bayer
- Class
- Mechanism of Action Protein 30S ribosomal subunit inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Gram-positive infections
Most Recent Events
- 02 Feb 1998 New profile
- 02 Feb 1998 Preclinical development for Gram-positive infections in Germany (Unknown route)